MetaCap

Circle8 Group (CIRC) vs Standard BioTools (LAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Standard BioTools (LAB) has outperformed Circle8 Group (CIRC) over the past year, losing 54.3% versus a loss of 94.4%. Over five years, LAB leads with a -86.5% price change compared with -99.9% for CIRC. Standard BioTools is the larger company by market cap ($249.1 million vs $16.0 million), about 15.6 times the size, while Circle8 Group is growing revenue faster (-1.5% vs -6.2%).

Circle8 Group converts more of its revenue into profit, with a net margin of -13.6% versus -87.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CIRC-94.44%LAB-54.28%
+93%-5%-103%
Nov 21, 20251 yearNov 20, 2026
CIRC-99.88%LAB-85.95%
+10%-48%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CIRC versus LAB key metrics
MetricCIRCLAB
Share price$0.1361$0.631
Market cap$15.99M$249.11M
1-day change-12.25%+2.82%
YTD return-89.77%-50.70%
1-year return-94.44%-54.28%
5-year return-99.88%-86.55%
EPS (TTM)$-2.14$-0.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$435.88M$85.33M
Revenue growth (YoY)-1.52%-6.24%
Net income (latest FY)$-59.43M$-74.90M
Gross margin10.55%49.86%
Operating margin-11.52%-129.20%
Net margin-13.63%-87.77%
52-week high$4.56$1.72
52-week low$0.136$0.39
Distance from 52-week high-97.02%-63.31%
Analyst consensus—none
Avg. price target upside—+113.95%
Average volume1.13M1.16M
Shares outstanding117.49M394.79M
Employees300385
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Standard BioTools is about 15.6 times larger than Circle8 Group by market value ($249.11M vs $15.99M).
  • LAB has outperformed CIRC by 40.2 percentage points over the past year.
  • Circle8 Group is more profitable, keeping -13.6 cents of every revenue dollar as net income versus -87.8 cents for Standard BioTools.

About Circle8 Group

CIRC stock →

Circle8 Group, Inc. provides talent management services.

Industrials · Biotechnology: Laboratory Analytical Instruments · 300 employees

About Standard BioTools

LAB stock →

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.

Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees

CIRC vs LAB FAQ

Which is bigger, Circle8 Group or Standard BioTools?

Standard BioTools (LAB) is larger, with a market capitalization of $249.11M compared with $15.99M for Circle8 Group (CIRC).

Which stock has performed better over the past year, CIRC or LAB?

LAB returned -54.28% over the past 12 months, compared with -94.44% for CIRC (price return, excluding dividends). Past performance does not predict future results.

Are Circle8 Group and Standard BioTools in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons